SCHEDULE: Coastlands Capital Amends Camp4 Therapeutics Stake
Schedule 13G Amendment
Coastlands Capital LP filed an amendment to its Schedule 13G for Camp4 Therapeutics Corp, correcting a rounding error in its reported 9.99% beneficial ownership.
Summary
- Coastlands Capital LP and its affiliated entities filed Amendment No. 1 to their Schedule 13G for Camp4 Therapeutics Corp.
- The amendment's sole purpose is to correct a typographical rounding error in Item 11 (Percentage of Class) of the original Schedule 13G filed on September 16, 2025.
- The reporting persons, including Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC, and Matthew D. Perry, beneficially own 4,886,722 shares of Camp4 Therapeutics Corp common stock.
- This ownership represents 9.99% of the total class of securities.
- The percentage is calculated based on 20,161,073 shares of Common Stock outstanding on August 5, 2025, as reported in the Issuer's Form 10-Q, plus 26,681,053 shares issued in a private placement transaction that closed on September 11, 2025.
- The reported securities exclude shares of Common Stock issuable upon exercise of a pre-funded warrant in excess of the beneficial ownership limitation of 9.99%.
Sentiment
Score: 5
Explanation: The filing is an administrative correction of a rounding error in a beneficial ownership report. It has a neutral impact as it does not convey new substantive information about the company's operations or financial health, but rather corrects a minor detail in a compliance document.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future operations or financial performance, focusing solely on beneficial ownership reporting.
Industry Context
This filing is a routine disclosure of institutional ownership, common in sectors like biotechnology or pharmaceuticals where companies often rely on private placements and institutional investment. It reflects a standard compliance update rather than a strategic industry move.
Stakeholder Impact
- The impact on shareholders is minimal, as the filing primarily corrects a minor reporting error and does not alter the underlying beneficial ownership or company fundamentals.
- The filing confirms the continued significant institutional ownership by Coastlands Capital, which may provide some stability signal to other investors.
Key Dates
| Date | Description |
|---|---|
| 2025-08-05 | Date when 20,161,073 shares of Common Stock were reported outstanding in the Issuer's Form 10-Q for the quarter ended June 30, 2025. |
| 2025-09-10 | Date of event which required the filing of the original Schedule 13G statement. |
| 2025-09-11 | Closing date of a private placement transaction where 26,681,053 shares of Common Stock were issued. |
| 2025-09-16 | Date the original Schedule 13G was filed. |
| 2025-12-11 | Signature date for Amendment No. 1 to Schedule 13G. |
Keywords
Camp4 Therapeutics, Coastlands Capital, Schedule 13G, Beneficial Ownership, SEC Filing, Institutional Ownership, Common Stock, Private Placement
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.